Aura Biosciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 6.295 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 652.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Details
| Name | Aura Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 113 |
| Founded | 2007 |
| Ipo Date | 2021-10-29 |
| Ceo | Natalie Holles |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 14.00 |
| Isin | US05153U1079 |
| Cusip | 05153U107 |
| Cik | 1501796 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Natalie C. Holles | President, Chief Executive Officer and Director |
| Dr. J. Jill Hopkins M.D. | Chief Medical Officer and President of Research and Development |
| Amy Elazzouzi | Senior Vice President of Finance, Treasurer and Secretary |
| Susan Abu-Absi Ph.D. | Chief Operating Officer |
| Alex Dasalla | Head of Investor Relations and Corporate Communications |
| Julie Person | Chief People Officer |
| Patrick Nealon | Senior Vice President of Clinical Development Operations |
| Dr. Anthony Daniels M.D. | Vice President and Therapeutic Area of Head Ocular Oncology |
| Erica Kratz Ph.D. | Chief Regulatory and Quality Officer |
Contact
| Address | 80 Guest Street, 5th Floor, Boston, Massachusetts 02135, United States |
| Phone | 617 500 8864 |
| Website | https://www.aurabiosciences.com |